INTRODUCTION
The Advisory Committee on Vaccines of the Spanish Association of Paediatrics (CAV-AEP) updates its recommendations for vaccination of children and adolescents compared to last year 1 (Figure 1) taking into account the current scientific evidence on vaccine effectiveness, and vaccine safety, as well as the epidemiology of vaccine-preventable diseases in Spain.
We recommend reading the expanded version of these recommendations in the CAV-AEP website, which provides the detailed arguments that support It is very important to start vaccination between 6 and 12 weeks of life in order to minimise risks, and to complete it before 24 weeks for the monovalent vaccine or 32 weeks for the pentavalent vaccine. Doses must be given at least 4 weeks apart. Both doses may be given at the same time as any other vaccine. the recommendations. In addition, the recommendations for special situations and risk groups can also be found in the Online Vaccine Manual of the AEP. Table 1 presents a list with the vaccines currently included in the schedule. These recommendations are aimed at paediatricians, family physicians, nurses, midwives, families and in general at anyone wishing to obtain updated information on paediatric immunisations.
Our objectives are to promote adherence with official immunisation schedules and offer health care providers options for catch-up vaccination in individuals with incomplete vaccination and to expand individual protection with the vaccines that are currently not included in official immunisation schedules.
We pursue the above objectives taking into account the local epidemiological circumstances and prioritising safety as a key component.
(10) Varicella vaccine (Var).-2 doses: the first at age 15 months (age 12 months is also acceptable) and the second at age 3-4 years. The tetravalent vaccine (MMRV) may be used for the second dose. Susceptible patients outside the specified ages will be vaccinated with 2 doses of Var at least 1 month apart. (11) Human papillomavirus vaccine (HPV).-Universal routine vaccination of all girls and boys, preferably at age 12 years, to prevent oncological diseases associated with this virus. All 3 HPV vaccines are authorised for use in male individuals, although there is little data on the use of the HPV2 vaccine in this sex. Administration of 2 doses at age 12 years. The vaccination schedule depends on the vaccine used: for the tetravalent vaccine, a 2-dose series (at 0 and 6 months) aged 9 to 13 years and a 3-dose series (at 0, 2 and 6 months) in those aged ≥14 years; for the 2-valent and 9-valent vaccines, a 2-dose series (at 0 and 6 months) aged 9 to 14 years and a 3-dose series (at 0, 1-2 [depending on the vaccine used] and 6 months) in those aged ≥ 15 years. The HPV vaccine may be administered at the same time as the MenC, MenACWY, hepatitis A and B and Tdap vaccines. There are no data on its coadministration with the varicella vaccine, although it should not cause any problems.
From the CAV-AEP, we once again emphasise the goal of promoting the establishment of a unified immunisation schedule to uphold the principle of equality in disease prevention and in the services offered by the public health systems of all the autonomous communities of Spain.
We need to structure systems for debate to advance in other important aspects, such as improving Primary Care as the cornerstone of the National Health System and the setting where vaccination is performed, gaps in vaccination coverage addressed in specific age groups, populations and geographical areas, considering approaches to the co-funding of vaccines that are not included in official immunisation schedules, establishing a system for compensation of adverse events that, while rare and unpredictable, may result from vaccination, and developing a platform with information on all aspects of vaccination.
As has been done in other countries, we need to promote a new technological and scientific infrastructure at the national level for providing evidence-based advice on policy issues related to vaccination, as recommended by the WHO, which would allow the synchronization of the various scientific, social and health administration perspectives at play.
The AEP is open and willing to participate and collaborate with the Ministry of Health, Consumption and Social Welfare of Spain, the governments of the different autonomous communities and any other parties involved in tasks and processes aimed at improving immunisation.
VACCINATION AGAINST HEPATITIS B 2020 recommendation:
We recommend the vaccination of infants with 3 doses of hexavalent vaccine at 2, 4 and 11 months of age. Previously unvaccinated older children and adolescents will receive 3 doses of the monovalent vaccine in a 0-, 1-and 6-months schedule.
In Spain, the annual incidence of hepatitis B remains under 2 cases per 100 000 inhabitants. In 2016, a total of 530 cases were notified, corresponding to an incidence of 1.14 cases per 100 000 inhabitants. 2 Since 2018, every autonomous community initiate the hepatitis B series at age 2 months with the hexavalent vaccine.
Newborns of mothers who are HBsAg-positive or of unknown serologic status should be vaccinated as early as possible regardless of birth weight and always with the monovalent vaccine. They should also be given hepatitis B immune globulin in the first 12 hours post birth if the mother is HBsAg-positive. Newborns vaccinated at birth will adhere to the routine immunisation schedule for the first year of life, so they will receive a total of 4 doses of hepatitis B vaccine.
VACCINATION AGAINST DIPHTHERIA, TETANUS, PERTUSSIS, POLIOMYELITIS AND HAEMOPHILUS INFLUENZAE TYPE B 2020 recommendation:
We recommend a 2 + 1 schedule with the hexavalent vaccine at 2, 4 and 11 months. Children that have received the 2 + 1 series should be given DTaP-IPV, preferably, or Tdap-IPV at age 6 years and Tdap at age 12-14 years. We recommend vaccination with Tdap of all pregnant women in each pregnancy, preferably between 27 and 32 weeks of gestation, as early as possible within this window. In case of known risk of preterm birth, vaccination could be given starting at 16 weeks.
The 2 + 1 schedule is sufficiently immunogenic and allows optimising the use of available doses. Earlier administration of the first dose at 6 weeks post birth is allowed.
The goal of vaccination during pregnancy is to prevent pertussis in infants aged less than 3 months and to reduce transmission. Vaccination of pregnant women with Tdap is the priority, without neglecting the primary vaccination series, booster doses and vaccination of health care staff employed in obstetrics and paediatrics settings.
Vaccination of pregnant women is effective, preventing disease (90%-93%) and death (95%) in infants aged less than 2 months. 3 The vaccine is highly immunogenic, and some studies have found a higher immunogenicity when it is administered early at 13 to 25 weeks compared to after 26 weeks of gestation, 4 but further research is required to confirm that the incidence of pertussis in infants aged less than 2 months does not increase with the former schedule. If vaccination is performed in the third trimester, a higher level of antibodies is achieved if performed between 27 and 30 weeks of gestation. 5 Some authors recommend a 3 + 1 schedule in preterm infants, as studies in this subpopulation were carried out using this schedule, but it is unknown whether it is necessary. Many European countries maintain the 2 + 1, 6 which facilitates adherence to the schedule, as vaccination may be delayed or incomplete in some of these children.
Children that received a 2 + 1 primary vaccination series with hexavalent vaccine should be given a booster dose at age 6 years, preferably with the DTaP-IPV vaccine.
Due to the increase in the incidence of poliomyelitis caused by wild poliovirus in Pakistan and Afghanistan, it is important to be careful in case of international travel.
VACCINATION AGAINST PNEUMOCOCCAL DISEASE
2020 recommendation: Vaccination against pneumococcal disease is recommended for all children younger than 5 years and children that are at risk due to underlying disease at any age. A 2 + 1 series (at 2, 4 and 11 months) is recommended for routine vaccination of infants. The CAV-AEP continues to recommend the use of the 13-valent pneumococcal conjugate vaccine (PCV13) on account of the current epidemiology of pneumococcal infections in Spain prior to the introduction and use of this vaccine.
The impact of pneumococcal conjugate vaccines (decavalent [PCV10] and VNC13) on invasive pneumococcal disease (IPD) and non-invasive pneumococcal disease caused by vaccine serotypes has resulted in few cases of IPD being caused by these serotypes. Childhood vaccination is expected to achieve the near eradication (90% decrease) of IPD by vaccine serotypes within 10 years if high vaccination coverage rates are achieved. Therefore, the future impact of pneumococcal conjugate vaccines will depend on replacement by nonvaccine serotypes and the ability to maintain high vaccination coverage.
The increase in IPD caused by nonvaccine serotypes reflects changes in nasopharyngeal carriage, which aside from vaccination is determined by complex factors that are difficult to control, such as the invasiveness of specific serotypes. 7 This explains the observed variability in replacement in different countries, even those using the same vaccine.
The increase in IPD by nonvaccine serotypes, which has been greater in the population aged more than 65 years, reduces, but does not nullify, the overall benefits of vaccination. 7, 8 Another factor at play is the phenomenon of serotype replacement, which can change the distribution of the different forms of IPD.
The United States is an exception in serotype replacement, as there has been no evidence of an increase in the incidence of IPD by nonvaccine serotypes in any age group. 7, 9 In Madrid, there has also been no increase in IPD by nonvaccine serotypes in individuals aged less than 15 years, but there has been an increase in other age groups in the incidence of IPD caused by serotypes 8, 3, 12F, 22F, 12B and 24F.
Although there has been a strong increase in the incidence of IPD by serotype 19A in countries using the PCV10, a study conducted in Kenya found that the incidence of IPD by this serotype did not change and did not detect replacement by other nonvaccine serotypes. 10 Recently, it has been confirmed that the level of specific antibodies required to prevent nasopharyngeal colonization (which is key to achieve herd immunity) is greater compared to the level required to prevent IPD and different for each serotype.
VACCINATION AGAINST ROTAVIRUS 2020 recommendation: Vaccination against rotavirus (RV) should be included in the routine immunisation schedule for al infants.
To date, more than 100 countries have introduced vaccination against RV in their immunisation schedules. The public health benefits of this intervention have been enormous, and in Europe vaccination programmes have led to reductions in the burden of disease of 60% to 90% both in terms of primary care visits and hospital admissions. 11 In Spain, a review of studies published in the past 10 years reveals a high effectiveness, with a reduction of 83% to 96% in the number of hospital admissions due to RV. 12 Vaccination also indirectly and positively affects the unvaccinated environment, which substantially enhances the impact and efficiency of this intervention. On account of their vulnerability, preterm infants deserve special attention, and they should receive the vaccine without delay, even if they are hospitalised, before 12 weeks post birth. 13 The benefits of vaccination far exceed the risk of intussusception, the only severe adverse event associated with the RV vaccine, which is very rare (1 to 5 cases per 100 000 vaccinated children). 14 
VACCINATION AGAINST MENINGOCOCCAL DISEASE 2020 recommendation: Routine vaccination against meningococcus B is recommended in all infants starting at 3 months of age with a 2 + 1 schedule. For all other age groups, including adolescents, the decision whether to vaccinate should be made on a case-by-case basis.
We also recommend administration of the MenC-TT vaccine at age 4 months and replacing the MenC dose at age 12 months by a dose of MenACWY. It is essential that, should a child not be given the latter vaccine, the dose of MenC is administered without fail. We continue to recommend administration of the MenACWY vaccine to adolescents, and catch-up vaccination is recommended up to age 18 years.
In Spain, 2 vaccines are available for prevention of invasive meningococcal disease (IMD) due to group B meningococcus: the 4CMenB vaccine (from age 2 months) and the MenB-fHbp vaccine (authorised in Europe for use from age 10 years), both of which contain subcapsular protein antigens.
Since IMD by serogroup B is rare, conventional costbenefit analyses of this vaccine are unfavourable. However, the CAV-AEP considers that it should be included in the routine immunisation schedule for 2 reasons: 1) IMD is a devastating disease and the most frequent serogroup isolated in infants aged less than 12 months in Spain is group B. 15 2) It is an effective vaccine, as demonstrated by its impact after the introduction in the vaccination schedule in England in 2015, with a 2 + 1 series given in infancy.
The outcomes after the first 10 months of the programme showed an effectiveness of 83% against all group B strains and a reduction of 50% in the number of cases in the target population. 16 Three years after its introduction, there is evidence of an overall adjusted effectiveness of 58.9% (95% confidence interval [CI], -31.5%-87.1%), and an effectiveness of 70.5% against strains theoretically covered by the vaccine. Since 2015, 277 cases of IMD due to group B meningococcus have been prevented, and the annual incidence observed in the 3 vaccinated cohorts has been lower than predicted, 17 with no evidence of safety concerns. It is possible that the 4CMenB vaccine may offer cross-protection against other serotypes.
Assuming the degree of uncertainty that is to be expected in relation to any recently developed vaccine, the CAV-AEP considers that there are sufficient data on its impact and safety to recommend administration of the 4CMenB vaccine to all infants, the age group with the highest incidence of IMD, with a 2 + 1 series starting at age 3 months. Tw o autonomous communities in Spain (Castilla y Leon and the Canary Islands) have already included the 4CMenB vaccine in their routine childhood immunisation schedules.
The CAV-AEP recommends vaccination against group B meningococcus in all adolescents to improve individual protection, but not as a routine measure, as these vaccines do not reduce the prevalence of nasopharyngeal carriage or generate herd immunity. 18 
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There is ample evidence of the effectiveness of the monovalent vaccine against group C meningococcus. The incidence rate of IMD due to serogroup C in Spain remained very low in the 2017-2018 season (0.08 cases/100 000 inhabitants). 14 Starting in 2000, there has been a marked increase in the incidence of IMD by serogroups W and Y in Europe, 19 leading many countries to change their vaccination policy against IMD by replacing the dose of MenC by a dose of Men-ACWY at age 2 years and/or in adolescence. Some countries in America, such as the United States, Canada, Chile and Argentina, have also included the MenACWY vaccine in their immunisation schedules. 20 In Spain, from the 2014-15 season, there has been an increase in the annual incidence of IMD, a trend that has been sustained year after year due to the increase in the incidence of IMD by groups W and Y. The latest data from the Centro Nacional de Epidemiología (National Epidemiology Centre), corresponding to week 32 of 2019, reflect a clear increase: 77 cases of IMD by group W (incidence, 0.16/100 000) and 48 by group Y (incidence, 0.10/100 000). 15 With these data, the Comisión de Salud Pública (Public Health Committee) published a document in 2019 with recommendations on vaccination against IMD. When it came to the MenACWY vaccine, the committee considered vaccination of adolescents and young adults a priority, replacing the MenC dose at 12 years by a dose of MenACWY and planning catch-up vaccination of adolescents aged 13 to 18 years in the span of 2 to 3 years to achieve an epidemiologically significant impact as soon as possible. 21 Meanwhile, the government of Castilla y León has included the Men-ACWY vaccine in the official immunisation schedule at ages 12 months and 12 years. Andalusia will add it to its routine schedule in 2020.
The CAV-AEP supports the replacement of the dose of MenC by a dose of MenACWY in adolescence, but also at age 12 months, given the increasing trend in the incidence of IMD by groups W and Y in children aged less than 5 years. In case the MenACWY vaccine is not given at 12 months, it is important to ensure administration of a dose of MenC to prevent a drop in vaccination coverage.
VACCINATION AGAINST MEASLES, MUMPS AND RUBELLA (MMR) 2020 recommendation: We recommend the administration of a first dose of MMR vaccine at 12 months of age, with a second dose given between 3 and 4 years of age. The tetravalent vaccine (MMRV) may be used for the second dose.
Due to suboptimal vaccination coverage in some countries, the prevalence of measles has exhibited a sustained increase in the past 6 years in 6 World Health Organization (WHO) regions. In the European Region, in the first semester of 2019, the incidence doubled compared to the same period in 2018, 22 and 4 countries have lost their measles-free status (not including Spain). There are still outbreaks of mumps, while rubella stays stable. 23 Maintaining vaccination coverage rates above 95% for the 2 doses and strict epidemiological surveillance are of the essence to eradicate these diseases.
Some studies have detected an increased risk of suffering convulsive seizures when the MMRV vaccine is used for the first dose given to children aged less than 2 years, so for the time being we recommend giving these 2 vaccines separately (MMR and varicella) in this age group. 24 VACCINATION AGAINST VARICELLA 2020 recommendation: We recommend vaccination of all children against varicella with 2 doses administered at ages 15 months and 3 ---4 years (the MMRV vaccine may be used for the second dose). We also recommend catch-up vaccination with a 2-dose series (or completion of the 2-dose series when applicable) for all children and adolescents that have not had the disease.
Since 2016, vaccination against varicella has been included in the immunisation schedule of every autonomous community with a 2-dose series (at 15 months and 3 ---4 years). 25 There are two monovalent and two tetravalent vaccines with evidence of a high effectiveness (92%---97.3%). 26 In 2019, 9 autonomous communities in Spain introduced the use of the MMRV vaccine for the second dose, facilitating adherence to the immunisation schedule.
The strategy of universal vaccination against varicella has proven cost-effective. 27 After 20 years of use in the United States, there is evidence of an overall decline in the incidence of disease 28 and in the incidence of herpes zoster in the paediatric population. 29 There is no evidence of shift toward older ages or of an increase in the incidence of herpes zoster in the overall population. 30 
VACCINATION AGAINST HUMAN PAPILLOMAVIRUS (HPV)
2020 recommendation: Routine vaccination against HPV is recommended in both girls and boys, preferably at age 12 years, as a means to prevent oncological diseases associated with this virus.
The optimal age for vaccination is 12 years, with administration of a 2-dose series, with the aim of maximizing immunogenicity and its possible benefits prior to sexual debut and pursuing the broadest possible vaccination coverage. The recommendation also extends to older ages if vaccination has been delayed, as well as to at-risk groups, given the benefits that it may continue to provide.
In girls, the evidence on the efficacy and effectiveness of this vaccine in preventing persistent HPV infection, genital warts and precancerous cervical lesions continues to grow, with a reduction of up to 85% in the incidence of high-grade dysplasias, even 10 years after vaccination. 31, 32 In male individuals, the efficacy of the vaccine in preventing HPV-related cancer is greater in those that receive it prior to their sexual debut. 33 These vaccines are extremely safe and have a very favourable risk-benefit ratio. 31 The only adverse events described are anaphylaxis, which may occur with administration of any vaccine, and syncope. 34 In spite of this, the coverage in Spain continues to be considerably low compared to all other vaccines in the routine immunisation schedule. 35 Vaccination of male individuals is already included in the schedules of 29 countries, with the recent addition of Germany and the United Kingdom. 34, 36 There are relevant data on the role of HPV in the aetiology of certain types of cancer affecting both sexes but with a higher incidence in males, such as rectal cancer and head and neck cancer. 37 The immunogenicity achieved is comparable to the one achieved in girls. 38 For all the above reasons, the CAV-AEP also recommends vaccination of male adolescents.
In Spain, 3 HPV vaccines are currently available: the 9-valent vaccine (HPV9), the 4-valent vaccine and the 2valent vaccine. 39, 40 All 3 confer protection against cervical cancer and precancerous lesions, although the first 2 also protect against genital warts. The HPV9 vaccine offers the widest direct coverage against cervical malignancies (90%) and potential prevention of HPV-related vulvar, vaginal and anal cancers (85%-95%). 41 All 3 are authorised for use in individuals of both sexes. In case vaccination against HPV is publicly funded, we recommend using the HPV vaccine that has been selected by each autonomous community.
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